12:19:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2023-04-27 16:39:28

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

On 16 February 2023, Qlife Holding AB ("Qlife" or the "Company") announced a rights issue of units of approximately SEK 57.7 million (the "Rights Issue"). The subscription period of the Rights Issue ended on 25 April 2023. Today, Qlife announces the outcome of the Rights Issue. The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unit rights. In addition, 56,332,035 units were subscribed for without unit rights, corresponding to approximately 9.8 percent of the Rights Issue, and underwriters subscribed for 397,627,615 units, corresponding to approximately 68.9 percent of the Rights Issue. Accordingly, the Rights Issue has been subscribed for to a total of 100 percent. The Company will thus receive total proceeds of approximately SEK 57.7 million before transaction costs, and upon full exercise of all warrants, Qlife will receive additional proceeds of a maximum of approximately SEK 67 million before transaction costs. Due to the completion of Rights Issue, a recalculation of the exercise terms for the Company's previously issued warrants series TO 2 has been carried out and has resulted in that the highest subscription price in the interval now amounts to SEK 9.27 and that each warrant series TO 2 entitles the right to subscribe for 1.08 new share in the Company. The other terms and conditions for warrants series TO 2 remain unchanged.

Subscription and allotment

The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unit rights. In addition, 56,332,035 units were subscribed for without unit rights, corresponding to approximately 9.8 percent of the Rights Issue, and underwriters subscribed for 397,627,615 units, corresponding to approximately 68.9 percent of the Rights Issue. Of the units subscribed for by underwriters, top guarantors subscribed for 165,694,250 units and bottom guarantors subscribed for 231,933,365 units. Accordingly, the Rights Issue has been subscribed for to a total of 100 percent. The Company will thus receive total proceeds of approximately SEK 57.7 million before transaction costs, which amount to approximately SEK 8.9 million. In the event of full exercise of all warrants issued, Qlife may receive additional proceeds amounting to approximately SEK 67 million before issue costs.

Each unit consists of one (1) share and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the rights to subscribe for one (1) new share in the Company at a subscription price of SEK 0.11. Subscription of shares by exercise of warrants will take place during the period 11 - 29 September 2023.

Allocation of units subscribed for without unit rights has been made in accordance with the allocation principles described in the EU Growth Prospectus that has been prepared in connection with the Rights Issue and published by the Company on 6 April 2023, and the supplementary prospectus that was published on 19 April 2023 (the "Prospectuses"). Notification regarding allocation will be made by posting a contract note to each subscriber. Allocated units shall be paid for in accordance with the instructions in the contract note.

Change in share capital and number of shares as well as dilution

Through the Rights Issue, the number of shares in Qlife increases with 576,813,400 shares, from 23,072,536 shares to 599,885,936 shares and the share capital increases by SEK 46,145,072.00 from SEK 1,845,802.88 to SEK 47,990,874.88. In the event of full exercise of all issued warrants series TO 3 for subscription of new shares in the Company, the number of shares will increase with additional 576,813,400 shares to a total of 1,176,699,336 shares and the share capital will increase by additional SEK 46,145,072.00 to SEK 94,135,946.88.

In connection with the Rights Issue, the Company has entered into agreements on guarantee commitments, in part of a so called bottom guarantee and in part of a so called top guarantee. For the bottom guarantee commitments, guarantee compensation is paid with sixteen (16) percent of the guaranteed and allotted amount, of which eight (8) percent of the fee will be paid in cash and eight (8) percent is to be offset against units to the same terms as in the Rights Issue. For the top guarantee commitments, guarantee compensation is paid with twenty (20) percent of the guaranteed and allotted amount, of which twelve (12) percent of the fee will be paid in cash and eight (8) percent is to be offset against units to the same terms and conditions as for the other guarantee commitments entered into in connection with the Rights Issue. The guarantee compensation in newly issued units is to be effectuated by a directed issue of units resolved by the board of directors as soon as the authorization granted by the extraordinary general meeting on 24 March 2023 is registered with the Swedish Companies Registration Office (Sw. Bolagsverket).

Trading in BTU

Trading in BTU (Sw. betald tecknad unit) takes place on Nasdaq First North Growth Market under the short name QLIFE BTU until the Rights Issue has been registered with the Swedish Companies Registration Office, which is estimated to take place around week 19, 2023. After approximately one week, BTU will then be converted to shares and warrants. Trading in the shares and warrants will thereafter take place on Nasdaq First North Growth Market as soon as possible after completed registration with the Swedish Companies Registration Office.

Warrants series TO 2

According to the original exercise terms for warrants series TO 2, each warrant entitles the right to subscribe for one new share in the Company during the period 7 - 21 June 2023 at a subscription price corresponding to 70 percent of the volume weighted average price of the Company's share on Nasdaq First North Growth Market during the period 22 May - 2 June 2023, however not more than SEK 10 per and not lower than the share's quota value. The full terms and conditions for the warrants are available on the Company's website, www.qlifeholding.com.

In connection with the completion of the Rights Issue, Öhrlings PricewaterhouseCoopers AB has, on behalf of Qlife, in accordance with the complete terms and conditions for warrants series TO 2, carried out a recalculation of the exercise terms. Recalculation has been made of the highest subscription price (i.e. SEK 10) as well as of the number of shares that each warrant series TO 2 entitles the right to subscribe for. The recalculation resulted in that the highest subscription price in the interval now amounts to SEK 9.27 and that each warrant series TO 2 entitles the right to subscribe for 1.08 new share in the Company. The other terms and conditions for warrants series TO 2 remain unchanged.

Advisers

G&W Fondkommission acts as financial advisor and Setterwalls Advokatbyrå AB acts as legal advisor to Qlife in connection with the Rights Issue. Aqurat Fondkommission AB acts as issuing agent in connection with the Rights Issue.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 2023-04-27 16:39 CET.